Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline.
TDM of psychotropic drugs is widely used, but there is little consensus regarding its optimal use in the clinical context. This prompted a multidisciplinary group comprised of clinical biochemists, clinical pharmacologists, and psychiatrists of the AGNP (Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie) to provide a consensus guideline. This will allow clinical psychiatrists, practitioners, and laboratory directors involved in psychopharmacotherapy to optimize TDM of antidepressants, antipsychotics, and opioid substituents. Recommendations are also given on the combined use of TDM and pharmacogenetic tests.
Baumann
P
P
Unité de Biochimie et Psychopharmacologie Clinique, Département Universitaire de Psychiatrie Adulte, CH-1008 Prilly-Lausanne, Switzerland. pierre.baumann@inst.hospvd.ch
Hiemke
C
C
Ulrich
S
S
Gaertner
I
I
Rao
M L
ML
Eckermann
G
G
Gerlach
M
M
Kuss
H J
HJ
Laux
G
G
Müller-Oerlinghausen
B
B
Riederer
P
P
Zernig
G
G
D016903:Drug Monitoring / Q000379:methods / Q000592:standards*; D006801:Humans; D017410:Practice Guidelines as Topic; D011619:Psychotropic Drugs / Q000097:blood* / Q000627:therapeutic use; D012016:Reference Values
D011619:Psychotropic Drugs